Clinical data required in 10% of 510(k)s, ODE Director Alpert says.
This article was originally published in The Gray Sheet
Executive Summary
RANDOMIZED TRIAL DESIGN REQUIRED FOR "LESS THAN 60%" OF IDEs Susan Alpert, MD, Director of FDA's Office of Device Evaluation, said March 18 at the Health Industry Manufacturers Association annual meeting in Palm Beach, Florida. Alpert noted that the figure on investigational device exemption studies reflects a "ratcheting up" of clinical data requirements in recent years, but also stressed that FDA has "not wound up with a single model" of clinical trial design. FDA's analysis included 50 ongoing IDEs.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.